• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Allergan resists $47B offer by swallowing poison pill

Allergan resists $47B offer by swallowing poison pill

April 23, 2014 By Arezu Sarvestani

Allergan fends off hostile $47B offer by swallowing poison pill

Aesthetics products maker Allergan (NYSE:AGN) last night adopted a "poison pill" strategy designed to insulate the company from a surprise $47 billion hostile takeover.

Allergan leadership said its new stockholder rights plan isn’t designed to prevent a potential acquisition, but only to give the company additional time to consider an unsolicited offer from Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and Pershing Square Capital Management hedge fund.  

Valeant announced yesterday that it had teamed up with Pershing to offer $48.30 in cash and 0.83 shares of Valeant common stock for each Allergan share, representing a premium of more than 7% over the company’s Monday night closing price. AGN stock soared following the announcement, and shares are up 26% since the start of the week.

Allergan responded less enthusiastically to the news, announcing that the board of directors opted to adopt a 1-year plan to grant 1 preferred share purchase right on each outstanding share of the company’s common stock. Commonly called a "poison pill," the strategy allows stakeholders other than the bidder to buy additional shares at a discounted price, potentially deterring would-be bidders by increasing costs.

Under the terms of Allergan’s plan, the new rights become exercisable if any one person or group acquires 10% or more of the company’s common stock. Pershing this month acquired a 9.7% stake in the company, according to regulatory filings.

Valeant CEO Michael Pearson told reporters today that he was disappointed but undeterred by the poison pill strategy.

"I think this deal will get done," he said during an interview with CNBC.

Valeant said in regulatory filings that the direct-to-shareholder acquisition bid came after a year and a half of failed attempts to negotiate with Allergan leadership.

"Unfortunately, Allergan’s management has not been receptive to our overtures for over 18 months and has made it clear privately and publicly that it is not interested in a deal with us, so we chose to take our proposal to Allergan’s shareholders directly," Valeant said. "We are committed to taking whatever steps are necessary to complete this transaction."

The merger would make the combined companies one of the largest drug firms in the world. Pearson has said he aims to get Valeant in the top 5, and the company has been making big bets on acquisitions. The company earlier this year closed a $250 million buyout of Solta Medical. Valeant last year made an $8.7 billion offer for Bausch & Lomb.

Filed Under: Cosmetic/Aesthetic, Mergers & Acquisitions, News Well, Wall Street Beat Tagged With: Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy